

**How to
 Use This
 Document**

This document is intended to summarize updates to the Wellfleet Rx National Preferred Formulary since the last formulary print version from 4/1/2020. These updates include both positive changes to existing formulary statuses and updates for newly approved medications. For all other medications not listed below, refer to the July 2020 National Preferred Formulary for information on formulary status.

Positive Changes Effective 7/1/2020 for All Users

Move to Preferred Status

Cardiovascular Disease	NEXLETOL (MAINTAIN PA)	Trade Relations Strategy
Eye – General Disorders	ZIOPTAN (ADD ST)	Trade Relations Strategy
Infectious Disease	BAXDELA (MAINTAIN PA)	Trade Relations Strategy
Neoplastic Disease	MVASI (MAINTAIN PA) ZIRABEV (MAINTAIN PA) KANJINTI (MAINTAIN PA) TRAZIMERA (MAINTAIN PA) RUXIENCE (MAINTAIN PA)	Trade Relations Strategy
Other Drugs	ORFADIN (ADD PA)	Trade Relations Strategy

Remove Step Therapy

Contraceptive	NATAZIA	Clinical/Safety Strategy
---------------	---------	--------------------------

New Drug Updates - Generics

Allergy	AZELASTINE-FLUTICASONE
Endocrine	INSULIN LISPRO PROTAMINE MIX
Hematological Disorders	DEFERASIROX
Immunosuppression	EVEROLIMUS
Other Drugs	MOXIFLOXACIN OPHTHALMIC

New Drug Updates – Preferred Brands

Endocrine	TRIJARDY XR (ST)
Neoplastic Disease	AYVAKIT (PA) TAZVERIK (PA)
Other Drugs	PALFORZIA (PA)
Seizure Disorder	VALTOCO

New Drug Updates – Non-Preferred Brands



July 2020 Changes National Preferred Formulary

Behavioral Health	CAPLYTA (ST, QL)
Hematological Disorders	ESPEROCT
Miscellaneous	TEPEZZA (PA)
Pain Management	NURTEC ODT (PA) REYVOW (PA) UBRELVY
Seizure Disorder	XCOPRI (ST)

Please note: The bolded medications are brands with a generic available.